Neurizon Therapeutics says it expects a registrational readout for NUZ-001 in 2027 as the company moves its oral, repurposed candidate through the HEALEY ALS Platform Trial toward a potential pivotal result.
NUZ-001 was repurposed from a veterinary product and targets the accumulation of misfolded proteins, with particular relevance to TDP-43 aggregation, which underlies the majority of ALS cases.
Preclinical models showed reductions in TDP-43 inclusions and preservation of proteins critical for motor neuron health. Human cellular studies complemented these findings by preventing formation of TDP-43 inclusions and maintaining markers of neuronal function.
Additional data indicate NUZ-001 activates multiple clearance pathways, including autophagy and proteasomal systems, suggesting potential applicability beyond ALS to other proteinopathy-driven disorders.
In a Phase 1 study and an open-label extension, a small cohort treated with NUZ-001 demonstrated slowing of functional decline, stabilisation of respiratory measures and biomarker trends consistent with reduced neuronal injury.
Comparisons against matched historical controls from the PRO-ACT database estimated meaningful survival benefits, though Neurizon and independent observers emphasise that these findings are preliminary and require confirmation in a randomised setting.
NUZ-001 was entered into Regimen I of the HEALEY ALS Platform Trial as a randomised, double-blind, placebo-controlled adaptive Phase 2/3 study. Regimen I enrolled 250 participants with a 3:1 active to placebo allocation and completed recruitment in under five months, the fastest enrollment recorded in the platform to date. The trial design prioritises a 36-week blinded period to allow treatment effects to separate from placebo trajectories. The primary endpoint is change in ALSFRS-R at Week 36, with secondary endpoints addressing respiratory function and survival and an extensive exploratory biomarker program to probe mechanism and disease biology.
